A phase I/II trial of MCLA-128

Trial Profile

A phase I/II trial of MCLA-128

Planning
Phase of Trial: Phase I/II

Latest Information Update: 15 Jul 2016

At a glance

  • Drugs MCLA 128 (Primary)
  • Indications Cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 15 Jul 2016 New trial record
    • 12 Jul 2016 According to a Merus media release, the company expects to file an Investigational New Drug (IND) application with the US FDA for this trial by the end of 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top